PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Girard N, Smit HJM, Sibille A, Mcdonald F, Mornex F, Garassino MCC, Filippi AR, Peters S, Field JK, Christoph DC, Fietkau R, Haakensen VD, Bar J, Chouaid C, Bray V, Kao S, Sawyer W, Allen A, Licour M, Garrido P (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Publisher: ELSEVIER

City/Town: AMSTERDAM

Pages Range: S939-S940

Conference Proceedings Title: ANNALS OF ONCOLOGY

DOI: 10.1016/j.annonc.2021.08.1775

Authors with CRIS profile

Involved external institutions

Institut Curie France (FR) Rijnstate Ziekenhuis Netherlands (NL) Centre Hospitalier Universitaire de Liège (CHU Liège) Belgium (BE) Royal Marsden Hospital / The Royal Marsden NHS Foundation Trust United Kingdom (GB) Hospices Civils de Lyon (CHU) France (FR) University of Chicago United States (USA) (US) Policlinico San Matteo Pavia Fondazione IRCCS Italy (IT) Lausanne University Hospital / Centre hospitalier universitaire vaudois (CHUV) Switzerland (CH) The University of Liverpool United Kingdom (GB) Kliniken Essen-Mitte Germany (DE) Oslo University Hospital / Oslo Universitetssykehus Rikshospitalet Norway (NO) Chaim Sheba Medical Center at Tel HaShomer / המרכז הרפואי עש חיים שיבא – תל השומר‎‎ Israel (IL) Hôpital Intercommunal de Créteil (CHIC) France (FR) Liverpool Hospital Australia (AU) Chris O’Brien Lifehouse Australia (AU) AstraZeneca UK Limited United Kingdom (GB) Universidad de Alcalá (UAH) Spain (ES)

How to cite

APA:

Girard, N., Smit, H.J.M., Sibille, A., Mcdonald, F., Mornex, F., Garassino, M.C.C.,... Garrido, P. (2021). PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. In ANNALS OF ONCOLOGY (pp. S939-S940). AMSTERDAM: ELSEVIER.

MLA:

Girard, N., et al. "PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy." Proceedings of the ANNALS OF ONCOLOGY AMSTERDAM: ELSEVIER, 2021. S939-S940.

BibTeX: Download